Zanubrutinib (BRUKINSA®) is a preferred regimen for second-line and subsequent therapy for Mantle Cell Lymphoma in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)3

Powerful Consistent Responses

84% of patients responded to BRUKINSA across both studies1

Study 206
PET-BASED
84
% ORR
59
% CR
Study 003
CT-BASED
84
% ORR
22
% CR

Median follow-up time was 18.4 months for Study 206 and 18.8 months for Study 0034

The efficacy of BRUKINSA was IRC-assessed in 2 clinical trials that included a total of 118 adult patients with MCL who received at least 1 prior therapy. Study BGB-3111-206 (Study 206): N=86, Phase 2, open-label, multicenter, single-arm trial; PET scans were required for response assessment. Study BGB-3111-AU-003 (Study 003): N=32, Phase 1/2, open-label, multicenter, single-arm trial; PET scans were not required for response assessment and the majority of patients were assessed by CT scan.

BTK=Bruton's tyrosine kinase; CI=confidence interval; CR=complete response; CT=computed tomography; IRC=independent review committee; ORR=overall response rate; PBMCs=peripheral blood mononuclear cells; PET=positron emission tomography.

View Efficacy Results

Complete
BTK Inhibition

Brukinsa Difference

Demonstrated
Safety Profile

Safety

Flexible
Dosing

Dosing
myBeiGene

Personalized Patient
Support Program

Patient Support